text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 61413-54-5 | Product Number: R0110

Rolipram


Purity: >98.0%(HPLC)
Synonyms:
  • 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
Product Documents:
50MG
$198.00
2   Contact Us 28  
250MG
$686.00
1   Contact Us 4  

* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.


Product Number R0110
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__6H__2__1NO__3 = 275.35 
Physical State (20 deg.C) Solid
Storage Temperature Frozen (-20°C)
Condition to Avoid Heat Sensitive
Packaging and Container 250MG-Glass Bottle with Plastic Insert (View image),  50MG-Glass Bottle with Plastic Insert (View image)
CAS RN 61413-54-5
Reaxys Registry Number 1588548
PubChem Substance ID 253659657
Merck Index (14) 8251
MDL Number

MFCD00270906

Specifications
Appearance White to Orange to Green powder to crystal
Purity(HPLC) min. 98.0 area%
Melting point 130.0 to 134.0 °C
Properties (reference)
Melting Point 132 °C
GHS
Related Laws:
RTECS# UY5749237
Transport Information:
HS Number 2933.79.1500
Application
Rolipram: A Selective PDE4 Inhibitor

Rolipram is a selective inhibitor of phosphodiesterases 4 (PDE4s) originally developed as an antidepressant agent in 1990s, but fell out of favor because of its undesirable gastrointestinal side effects. Nowadays, rolipram continues to be used in research as a PDE4 inhibitor. PDE4s are responsible for hydrolysis of the cyclic nucleotides cAMP [A2381] and cGMP to 5’-AMP [A0158] and 5’-GMP [G0338], particularly in nerve and immune cells. The inhibition of PDE4s by rolipram induces the elevation of intracellular cAMP concentration. Consequences rolipram-induced elevation of cAMP suppress expression of proinflammatory cytokines and other mediators of inflammation. Rolipram has been reported as a drug for the treatment of autoimmune diseases, Alzheimer's disease, cognitive enhancement, and respiratory diseases like asthma and COPD. Rolipram is a racemic compound, and (R)-rolipram [R0182] is more potent than (S)-rolipram [R0183] as a PDE4 inhibitor. (The product is for research purpose only.)

References


PubMed Literature


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.